ReviewAnalytical and bioanalytical chemistry2026
Next-generation electrochemical aptasensors for thrombin detection: the rise of aptamer-MOF architectures.
Review in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombin is a crucial regulatory enzyme in the blood coagulation cascade that significantly influences cancer metastasis, cardiovascular disease, inflammation, and immunological regulation. Because of its dynamic, concentration-dependent activity, thrombin has emerged as a potential biomarker for the early diagnosis of a wide range of pathological conditions. However, a common drawback of typical thrombin assays is their insufficient specificity, sensitivity, and operational simplicity required for point-of-care or real-time applications. The latest developments in coordination chemistry have resulted in the discovery of metal-organic frameworks (MOFs). These crystalline porous materials have been demonstrated to be robust biosensing platforms due to their extensive surface area, customizable functionality, and biocompatibility. Hence, integrating them with aptamers, synthetic oligonucleotides with remarkable molecular specificity and binding affinity, has led to the emergence of the next generation of electrochemical biosensors called MOF-based aptasensors. The metal-organic framework-based aptasensing strategies outperform current techniques. This review focuses on advancements in MOF-aptamer hybrid platforms and explores their potential to transform from laboratory-scale investigations into clinically viable technologies. Additionally, the study covers a decade of progress from 2015 to 2025, with a focus on innovations in sensor architecture, signal amplification strategies, material synthesis, and clinical applications. Aptamer-MOF complex-based biosensing platforms could revolutionize thrombin diagnosis. This approach leverages molecular diagnostics and supramolecular chemistry to make highly sensitive, portable, and clinically useful devices. This work provides a direct comparative assessment of the clinical performance of MOF-aptamer sensing platforms, classifying them by metal-core chemistry and amplification method. It also outlines commercial and regulatory challenges as well as potential translational prospects. This comprehensive review serves as a design blueprint for developing next-generation biosensors targeting thrombin and other coagulation-related biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.